Drugs /

sym015

Back to Drugs List

Overview

NCI Definition [1]:
A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the extracellular domain of the human hepatocyte growth factor receptor (MET; HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-MET monoclonal antibody mixture Sym015 targets and binds to the extracellular domain of MET, thereby preventing the binding of its ligand, hepatocyte growth factor (HGF). This may prevent activation of the receptor and MET-mediated signal transduction pathways. This inhibits MET-dependent tumor cell proliferation. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.

Clinical Trials

View Clinical Trials for sym015

Sym015 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating sym015, 1 is phase 1/phase 2 (0 open).

MET Amplification is the most frequent biomarker inclusion criterion for sym015 clinical trials.

Malignant solid tumor is the most common disease being investigated in sym015 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Sym015
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sym015 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hu9006-hu9338, anti-met monoclonal antibody mixture sym015, sym 015, sym-015, hu9006/hu9338
Drug Target(s) [2]:
MET
NCIT ID [1]:
C127906

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.